All In Biotech

Drug Trial Radar · NCT05405725

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 504 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

504

Actual

Start

Jul 4, 2022

Primary completion

Jul 18, 2024

Study completion Jul 18, 2024

Sponsor

Lead sponsor
Enzene Biosciences Ltd.Industry
Sponsor type
Industry
Collaborators
Alkem Laboratories Ltd
First posted
Jun 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis. The primary goal for the study is 1. To evaluate the efficacy of ENZ215 when compared to Prolia® in patients with postmenopausal osteoporosis, in terms of change in BMD at the lumbar spine from baseline to Month 12 and 2. To compare the AUEC of sCTX levels from baseline to Month 6

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • ENZ215Biological

    Enrolled women with postmenopausal osteoporosis receive ENZ215 (60mg)

  • ProliaBiological

    Enrolled women with postmenopausal osteoporosis receive Prolia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.Time frame: Month 12
  2. Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) LevelsTime frame: Month 6

Locations

48 sites in 7 countries. Site status is shown where the registry gives one.

  • University Hospital

    Plovdiv, Bulgaria

  • Medical Center Teodora,

    Rousse, Bulgaria

  • DCC XVII-Sofia EOOD

    Sofia, Bulgaria

  • Research Center(Medical Center Synexus Sofia EOOD)

    Sofia, Bulgaria

  • Research Center

    Brno, Czechia

  • G-CENTRUM Olomouc

    Horní Město, Czechia

  • Research Center

    Pardubice, Czechia

  • University Hospital.

    Pilsen, Czechia

  • Synexus Czech

    Prague, Czechia

  • Clinic

    Prague, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • MEDICAL PLUS s.r.o.

    Uherské Hradiště, Czechia

  • Sydvestjysk Sygehus Esbjerg

    Esbjerg, Denmark

  • JSC Saules seimos medicinos ce

    Kaunas, Lithuania

  • Hospital of Lithuanian University of Health Sciences Kauno klinikos

    Kaunas, Lithuania

  • Kaunas City Polyclinic

    Kaunas, Lithuania

  • Lithuanian University of Health Sciences Hospital

    Kaunas, Lithuania

  • Republican Siauliai Hospital

    Šiauliai, Lithuania

  • Vilnius University Hospital Santaros Klinikos

    Vilnius, Lithuania

  • National Osteoporosis Center

    Vilnius, Lithuania

  • Osteo-Medic S.C. A Racewicz

    Bialystok, Poland

  • Szpital Uniwersytecki

    Bydgoszcz, Poland

  • Centrum Medyczne Pratia Czestochowa

    Częstochowa, Poland

  • Synexus Polska

    Częstochowa, Poland

  • Synexus Polska

    Gdansk, Poland

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Poland

  • Synexus Polska

    Gdynia, Poland

  • Silmedic sp. z o.o.,ul. Gen. Wladyslawa Sikorskiego

    Katowice, Poland

  • Synexus Polska

    Katowice, Poland

  • ETG Kielce, ul. Zagorska

    Kielce, Poland

  • Krakowskie Centrum Medyczne

    Krakow, Poland

  • ETG Lodz, ul. Pilota Stanislawa Wigury

    Lodz, Poland

  • Synexus Polska

    Lodz, Poland

  • ETG Lublin, ul. Kunickiego

    Lublin, Poland

  • Twoja Przychodnia Nowosolskie Centrum Medyczne,

    Nowa Sól, Poland

  • Prywatna Praktyka Lekarska

    Poznan, Poland

  • Synexus Polska

    Poznan, Poland

  • Twoja Przychodnia PCM

    Poznan, Poland

  • ETG Siedlce

    Siedlce, Poland

  • Twoja Przychodnia - Szczecinskie Centrum Medyczne

    Szczecin, Poland

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.